Interim report
Page 1
L1JENBURKT Jenburkt Pharmaceuticals Limited Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127 Ref. No. JPL/CS/2251/2025 Date: 28" October, 2025. To BSE Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Sub.: Outcome of Board Meeting held today, i.e. 28"" October, 2025 —Standalone Unaudited Financial Results for the quarter and half year ended on 30 September, 2025. Reg.: Regulation 30(2) and 33 of SEBI Regulation, 2015. isting Obligations and Disclosure Requirements Dear Sir, 1. The Standalone Unaudited Financial Statements for the quarter and half year ended on 30" September, 2025 have been approved and adopted by the Board, on the recommendation of Audit Committee, vide their meeting held on even date. The same has been attached herewith in the format required under Regulation 33(4) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, along with statement of standalone Assets & Liabilities as at 30'" September, 2025 and Cash Flow statement for the half year ended on 30" September, 2025, as annexure A and B respectively. 2. The Limited Audit Review Report dated 28" October, 2025, of Auditors of the Company, on the standalone unaudited financial results for the quarter ended on 30" September, 2025, is also attached. The Board Meeting commenced at 2.30 p.m. and was concluded at 04.15 p.m. Kindly take on record the above and acknowledge. Thanking you, Encl.: As Stated Above. & w = i: Science hai toh Hope hai 3 Hope hai toh Health hai #3 Health hai toh Happiness hai 3 ** aa Email: info@jenburkt.com www.jenburkt.com CIN No, L24230MH1985PLC036541 ae
Page 2
LAJENBURKT Jenburkt Pharmaceuticals Limited Regd. Office: 93, Jayprakash Road, Andheri (West), Mumbai - 400 058. Phone: 022-67 603 603 Fax: 91-22-66943127 Statement of Standalone Unaudited Financial Results for the Quarter & Half Year Ended on 30th September, 2025 (Rs. in Lacs other than EPS) Particulars Quarter Ended Year to Date Year Ended 30-09-2025 30-06-2025} 30-09-2024] 30-09-2025] 30-09-2024] 31-03-2025 Unaudited] Unaudited] Unaudited] Unaudited] Unaudited] Audited I Revenue from Operations 4555.76 3552.68 4121.59 8108.44 7375.16 15169.15 Tl Other Income 207.90 205.71 185.33 413.61 325.90 672.10 ill Total income (I + Il) 4763.66 3758.39 4306.92 8522.05 7701.06] 15841.25 IV Expenses (a){Cost of Materials Consumed 219.35 213.54 214.53 432.89 398.30 851.12 (b)]Purchase of Stock-in-trade 628.33 537.24 532.82 1165.57 1108.05 2126.08 Changes in inventories of Finished Goods, (c) Stock-in-trade and WIP -12.04 -99.02 80.42 -111.06 -49.58 -11.55 (d)}Employee benefit expenses 1393.25 1172.08 1251.90 2565.33) 2318.65 4553.58 (e)|Finance Costs 10.74 10.99 11.64 21.73 23.12 45.28 (f )}/Depreciation and Amortisation Expense 74.39 72.25 63.90 146.64 115.80 272.79 (g)}Other expenses 1016.44 833.11 899.43 1849.55 1528.31 3610.67 Total Expenses (IV) 3330.46 2740.19 3054.64 6070.65 5442.65] 11447.97 Vv Profit before tax (III - IV) 1433.20} 1018.20) 1252.28] 2451.40] = 2258.41] 4393.28 Vi Tax Expense (i)} Current Tax 400.00 200.00 300.00 600.00 550.00 1190.00 (ii) Income Tax for previous years 0.00 0.00 0.00 0.00 0.00 17.80 (iii) Deferred Tax 16.86 39.02 777 55.88 6.76 -20.58 vil Profit after tax for the period (V-VI) 1016.34 779.18 960.05 1795.52] 1701.65 3206.06 VII Other Comprehensive Income a| (i) Items that will not be reclassified to profit or loss -45.10 155.19 78.59 110.09 252.19 136.06 ..,jincome Tax relatiing to Items that will not (1) he reclassified to profit or loss 16.97 -17.76 21.93 -0.79 3.41 16.80 B| (i) Items that will be reclassified to profit or loss 0.00 0.00 0.00 0.00 0.00 0.00 _. {income Tax relatiing to Items that will be (ii) reclassified to profit or loss 0.00 0.00 0.00] 0.00 0.00] 0.00 Total Comprehensive Income for the am period (VII + VIII) 988.21 916.61 1060.57 1904.82 1957.25 3358.92 Paid up Equity Share Capital (F.V. Rs.10/- each) 441.33 441,33 441.33 441.33 441.33 441,33 Earnings Per Share (in Rs.) (F.V. Rs.10/-) x Basic and Diluted 23.03 17.66 21.75 40.68 38.56 72.65 Notes: 1 The above statement of standalone unaudited financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 28th October 2025. 2 The Company is dealing exclusively in Pharmaceuticals business segment, hence segment wise reporting is not applicable. 3 The Statement of Assets and Liablilites as at 30th Septemeber 2025 and Cashflow Statement for the half year ended on 30th Septemeber 2025 a are annexed as Annexure A & B respectively. (MA te. Ble ae (Ashish U. Bhut Chairman & Managing Director F™%, (DIN No: 00226479) Place : Mumbai Date : 28th October 2025 8 Science hai toh Hope hai 3% Hope hai toh Health hai #3 Health hai toh Happiness hai 3%: Email: info@jenburkt.com www.jenburkt.com CIN No. L24230MH1985PLC036541 pee
Page 3
Annexure - A Standalone Unaudited Statement of Assets and Liabilities as at 30th September, 2025 [=IJENBURKT Rs in Lacs Particulars Note 30/09/2025 31/03/2025 Amount Amount ASSETS (1) Non-current Assets (a) Property, Plants & Equipments 1 1142.35 1229.47 (b) Right to Use Asset 2 190.14 213.44 (c) Other Intangible assets 2 37.73 22.79 (d) Capital Work In Progress 3 5221.20 4027.67 (e) Financial Assets (i) |Investments 4 2725.93 2055.81 (ii) }Loans 5 1.30 1.90 (iil) | Other Financial Assets 6 6861.65 5990.89 Deferred Tax Asset 7 80.19 146.93 (f) Other Non-current Assets 8 109.16 276.54 (2) Current assets (a) Inventories 9 1017.49 888.03 (b) Financial Assets {i) |Trade Receivables 10 2275.47 2073.49 (ii) |Cash and Cash Equivalents 11 543.50 736.48 (iii) | Bank Balance other than (iii) 12 421.33 1728.11 (iv) |Loans 13 39.15 5.20 (v) |Other Financial Assets 14 37.10 40.30 (c) Other Current Assets 15 187.29 165.73 Current Tax Asset (Net) 16 15.81 15.81 Total Assets 20,906.79 19,618.60 EQUITY AND LIABILITIES (1) Equity (a) Equity Share Capital 17 441.33 441.33 (b) Other Equity - Reserves & Surplus 18 17,846.80 16,736.38 Liabilities (2) Non-current liabilities (a) Financial Liabilities (i) |Lease Liabilities 19 126.73 149.19 (ii) |Other Financial Liabilities 20 301.03 301.03 (b) Deferred Tax Liability 7 98.67 108.74 (3) Current Liabilities (a) Financial Liabilities (i) |Lease Liabilities 21 44,03 42,31 (ii) |Borrowings 22 - 197.88 (iii) | Trade Payables (A) Total Outstanding dues of Micro Enterprises and 23 20.36 16.56 Small Enterprises; and (B) Teta Outstanling dues of creditors other than 33 933.84 798.97 Micro Enterprises and Small Enterprises. (iv) |Other Financial Liabilities 24 658.19 467.93 (b) Other Current Liabilities 25 167.49 169.29 (c) Provisions 26 103.36 160.40 (d) Current Tax Liabilities (Net) 16 164.94 28.59 Total Equity and Liabilities 20,906.79 19,618.60 Place : Mumbai Date : 28th October, 2025 By order of the Board or Jenburkt Pharmaceuticals Ltd. (Mot Le Ble (asHisi U BHUTA) AAIRMAN AND MANAGING DIRECTOR {> (DIN No: 00226479)
Page 4
Annexure - B LdJENBURKT Unaudited Cashflow Statement for the half year ended on 30th September, 2025 Rs in Lacs 30-09-2025 31-03-2025 A. CASH FLOW FROM OPERATING ACTIVITIES : a Net Profit After Tax 1,795.51 3,206.06 Adjustments for : i |Depreciation and Amortisation Expense 146.64 272.79 ii |Loss on Fixed Assets scrapped 0.19 3.39 iii | Tax Expense 655.88 1,187.22 iv |Finance Cost 21.73 45.28 v |Interest Income (279.02) (526.22) vi | Dividend income (7.19) (8.73) vii | Unrealsied Gain on Investment at Fair Value 0.28 (5.17) viii] Gain on sale of investment (Short Term Capital Gain / Loss) (23.29) (80.59) ix | Provision/write off for doubtful trade receivables/advances (187.42) 7.92 x |Unrealised Foreign Exchange gain (64.52) (19.36) xi |Others 0.96 1.92 Operating profit (Loss) before working capital changes 2,059.75 4,084.49 b MOVEMENTS IN WORKING CAPITAL i |Increase or (Decrease) in Inventories (129.47) (31.86) ii |Increase or (Decrease) in Trade Receivables 49.95 (114.53) iii {Increase or (Decrease) in Other (Current & Non Current) Assets 145.99 (141.33) iv |Increase or (Decrease) in Trade Payables 138.67 189.81 v_ |Increase or (Decrease) in Bank Borrowings (197.88) 197.88 vi {Increase or (Decrease) in Other (Current & Non Current) Liabilities 197.73 (114.30) vii |Current & Non Current Financial Loans (33.35) 4.99 viii | Increase or (Decrease) in Provisions (57.04) 58.74 c Cash used in operation 2,174.36 4,133.91 i |Income Taxes paid (Net of Refund) (463.65) (1,343.31) Net cash used in operating activities (A) 1,710.71 2,790.60 B. CASH FLOW FROM INVESTING ACTIVITIES : i |Payments for purchase of Property, Plant and Equipment (Including Capital Work (1,244.87) (1,971.36) in Progress, Intangible Assets and Intangible Assets in Development) ii |Proceeds from disposal of property, plant and equipment and intangible assets - - ii | Purchase of Investments (2,951.93) (3,762.77) iii | Proceeds from Sale / Redemption of Investments 2,414.91 3,616.29 iv |Other Bank balances not considered as cash and cash equivalents - Bank Fixed Deposit made during the year (5,349.00) (15,287.38) - Bank Fixed Deposit matured during the year 5,959.93 15,155.72 v |Interest Received 108.22 536.30 vi | Dividend Received 7.19 8.73 Net cash generated by investing activities (B) (1,055.55) (1,704.47) c. CASH FLOW FROM FINANCING ACTIVITIES : i |Finance Cost (22.79) (28.04) ii |Dividend paid (797.30) (678.05) iii |Repayment of Lease Liabilites (28.05) (56.10) Net cash used in financing activities (C) (848.14) (762.19) NET INCREASE/DECREASE IN CASH AND CASH EQUIVALENT (A+B+C) (192.98) 323.94 Cash and cash equivalent at the beginning of the year (1st April, 2024) 736.48 412.54 Cash and cash equivalent as at the end of the year (30th September, 2025) 543.50 736.48 (192.98) 323.94 By order of the Board or Jenburkt Pharmaceuticals Ltd. N Li Le. he & Oey (ASHISH U BHUTA) * CHS RIMIAN AND MANAGING DIRECTOR Place : Mumbai Date :28th October, 2025
Page 5
D.R.MEHTA & ASSOCIATES (CHARTERED ACCOUNTANTS) H-2, EVEREST BUILDING, 97™# FLOOR, TARDEO CIRCLE, MUMBAI - 400034 TEL: 23513758 / 23520330 FAX: 666072638, 9322508373 Email ID: info@drmehta.in, vikram@drmehta.in, ashok@drmehta.in Limited Review Report on Unaudited Quarterly Standalone Financial Results of Jenburkt Pharmaceuticals Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015 To the Board of Directors of Jenburkt Pharmaceuticals Limited We have reviewed the accompanying statement of unaudited standalone financial results of JENBURKT PHARMACEUTICALS LTD for the quarter ended 30" September 2025 (the statement). This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) “Interim Financial Reporting” prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement. Our conclusion is not modified in respect of this matter. \ For D.R.Mehta & Associates eo Chartered Accountants Lo Jo: BAT (Firm Reg. No. 106207W) Wesf v5, uo. WN wor a Partner \ Kh Vikram Mehta a (Membership No. 47347) UDIN: 25047347BMKQID6215 Place: Mumbai Date: 28" October 2025